NIH modernization could expose biosafety gaps

As a life science project progresses, it can travel through different domains of science, or at least the purviews of different government regulators. A project to produce novel molecules might start off looking like chemistry—it may not implicate biosafety policies. But if researchers introduce those molecules into cultured cells, the regulatory picture changes. If plants are involved, agricultural oversight may follow. Should the technology move toward industrial or medical use, still other federal agencies may have jurisdiction. Federal science oversight is a complex web that institutions must navigate largely by themselves. For the last 50 years, they’ve relied on a particularly adaptive compass: the National Institutes of Health (NIH)’s recombinant DNA guidelines.

The guidelines have served as a shared reference point, creating infrastructure within institutions to interpret life science policies and a common language to communicate among researchers and the government. They were born from safety concerns about emerging genetic engineering research. Technically, they apply to NIH-funded work involving recombinant or synthetic nucleic acid molecules. But in practice, federal agencies and institutions across the United States have adopted the same committees, roles, biocontainment categories, and reporting structures for virtually all life sciences research, regardless of funding source or discipline. This shared structure has allowed a fragmented regulatory environment to function as a system.

That may soon change.

The NIH is engaged in biosafety oversight modernization discussions and appears to be in the process of prioritizing human-based science. Because the guidelines are tied to NIH funding, institutions maintain the programs necessary to remain eligible for NIH grants. If modernization makes a wide swath of biological research out of the scope of NIH’s new biosafety oversight policies—say, because it involves animal and not human-based research—institutions will have less of an obligation to maintain the structures that grew from the NIH guidelines.

Consider wildlife pathogen surveillance in bat colonies. Researchers collect biological samples and screen them for viruses to understand how pathogens circulate in wildlife populations. Although the work centers on disease ecology rather than human infection, laboratory analysis can involve amplifying viral genetic material for sequencing or culture. Under a new model that only considers human pathogens, this research may not receive the same level of oversight. Of course, bats are believed to be the reservoirs of several viruses that have spilled over into humans.

Some institutions might continue to invest in robust oversight programs; others might scale back. Biosafety review may no longer occur under shared national expectations. Identical research could receive very different levels of scrutiny, or none at all, depending solely on where it is conducted. 

A cohesive system. The NIH guidelines established the core oversight infrastructure that US research institutions now treat as standard. At the center of that infrastructure are institutional biosafety committees that include scientific subject matter experts and community representatives who review proposed research and determine if the risks of that research are appropriately identified and mitigated. Biological safety officers work with investigators to conduct risk assessments and develop safeguards to ensure experiments are conducted safely and responsibly. Facility containment standards ensure experimental products and materials stay secure. Incident reporting systems standardize the logging of accidents. Community participation builds public accountability. These elements form the backbone of biosafety oversight in the United States.

The same institutional biosafety committees and biological safety officers review research across the life sciences, from engineering yeast to producing a vaccine protein to work involving federally regulated select agents or other high-consequence biological materials. The guidelines may apply narrowly, but the oversight system institutions built to comply with them are used broadly. Having this infrastructure in place has become a common expectation across universities, companies, and federal partners.

This matters because biological research rarely stays in one domain. It may begin with bench-scale experiments, but transition to research on plants, animals, or even therapies for humans. Different federal agencies have separate rules for research at these different stages. The US Department of Agriculture (USDA) oversees certain animal and plant health research, particularly when regulated agricultural pathogens or field trials are involved. The Centers for Disease Control and Prevention (CDC) publishes biosafety guidance for laboratory containment levels, regulates the importation of infectious biological materials that could cause disease in humans, and oversees select agents in partnership with USDA.

The NIH guidelines do not replace those authorities, but they do provide the common framework that allows institutions to integrate them. The institutional biosafety committee can assess whether USDA regulations are being followed, for example. Without shared committee structures and standardized containment practices, institutions would face substantially greater challenges navigating the differing requirements of multiple agencies. At the same time, without a common framework, an experiment might be judged safe in one institution and unacceptable in another.

Necessary modernization. The current biosafety system works because it embeds accountability within institutions and follows research as it evolves. But it was designed in an era when recombinant DNA was the central concern and when the boundaries between laboratory research, clinical use, and environmental release were easier to define. That is no longer the case. Modern biology includes precision gene repair, transplantable animal organs, brain-like organoids, gene drives intended to alter wild populations, human, animal, and plant diseases, and programmable living systems such as synthetic cells. Researchers are debating mirror biology, engineered wildlife, and other novel biological platforms. Work moves fluidly between medicine, agriculture, and ecosystems. Risk does not stay confined to one category.

The existing infrastructure has adapted by stretching older definitions to cover new technologies. That flexibility has been a strength. It has also produced strain. Committees are asked to interpret frameworks written for a different scientific landscape. Institutions shoulder increasing responsibility for resolving ambiguities that federal policy has not yet addressed, for example, when an institutional biosafety committee must decide whether a non-replicating synthetic cell that contains DNA but behaves more like a chemical sensor should be reviewed under the NIH guidelines or chemical safety rules. Modernization is necessary not because the system failed, but because it is operating beyond its original design.

If the guidelines are limited to government-funded human health research, other domains of modern biology will either fall more squarely under separate agency authorities or be left to institutional discretion. Will there be biological safety officers or institutional biosafety committees that can deal with the breadth of life sciences regulation? If responsibility becomes more distributed across agencies, whether a cohesive biosafety system endures will depend on whether agencies develop a unified framework. A coordinated model for biosafety oversight, adopted government-wide and implemented by each agency, could preserve consistency. NIH’s current modernization efforts could be a catalyst in making this happen.

What cannot disappear is the clear point of accountability that has made biosafety oversight functional: institutional biosafety committees, biological safety officers, and transparent review processes that follow research wherever it goes. Without the system originally created by the guidelines in place, practices that are standard across institutions may disappear, and oversight may be applied unevenly. In the worst case, funding source and institutional capacity will matter more than the nature of the risk itself.

With clear alignment and consistent implementation, oversight that distributes authority can support continuous governance and reinforce public confidence rather than weaken it. Biosafety modernization should refine and extend the architecture brought about by NIH’s venerable guidelines, not replace it. If approached as an evolution rather than a reset, modernization can strengthen an already durable foundation.